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This study aims to conduct an in vitro study confirming the affinity of vascular 
cell adhesion molecule-1 (VCAM-1) specific peptide surface modified 
superparamagnetic iron oxide nanoparticles (SPIOs) for atherosclerosis plaque imaging. 
Currently, plaque detection technology is not as advanced as it could be to detect early 
onset of atherosclerosis. A novel method is to use biocompatible nanoparticles attracted 
to the specific sites of interest to image and remove the plaque before further damage. 
This in vitro can be translated into an in vivo model making it applicable in future 









BACKGROUND AND HISTORY 
Arthrosclerosis is a progressive, inflammatory disorder characterized by lesions or 
fatty streaks that develop into plaque deposits with a high risk of rupture and thrombosis. 
Atherosclerosis was initially identified in Egyptian mummies from 1500 BC. Until 
recently, the development of these plaque streaks has been a mystery.
1,4,5
  
Atherosclerosis is considered a gradual, insidious process caused by a 
combination of endothelial cell dysfunction, lipid oxidation, and lipid accumulation. 
Endothelial cell dysfunction occurs as cells are exposed to atherogenic milieu such as 
tobacco smoke, aging, and obesity. When the endothelial cells are damaged, adhesion 
molecules such as vascular cell adhesion molecule-1 (VCAM-1), and selectins, such as P-
selectin, are attracted to the site of injury and function as cell receptors. They signal the 




Atherosclerosis is notably known as a “gradual” process because the fatty streaks 
generally begin during early childhood and adolescence. Since developed at a young age, 
these plaques usually go undetected and eventually develop into more insidious, life 
threatening fat deposits which could instigate myocardial infarction or sudden cardiac 
death. Figure 1 depicts the development of atherosclerosis starting from the foam cells to 





If caught early on, these plaque deposits are reversible by mobilizing the lesions 
and removing them from the vessel wall by a process called reverse cholesterol transport 
which involves a sequence of enzyme-mediated reactions. In general, these enzymes 
cause the high-density lipoproteins (HDL) to mobilize the fatty deposits so that they can 
be cleared from the blood stream. If not removed, a stable plaque might grow for decades 
until it causes stenosis or occlusion, and an unstable plaque will grow vulnerable to 
spontaneous rupture or thrombosis. This rupture involves the secretion of 
metalloproteinases, cathepsins, and collagenases by activated macrophages which digest 






Shows the gradual 
progression of fatty 
streak development 
which progressively 
grows and becomes 






Current detection techniques, such as serum C-reactive protein (CRP), provide 
minimal data analysis that limits the assessment of cardiovascular risk. CRP is generally 
very low in healthy humans, however it significantly increases in patients with 
atherosclerosis even during early stages of development. Another imaging technique is a 
contrast angiography that helps to visualize the plaque, however, an angiography is 
unable to view the entire arterial wall thus eliminating its ability to identify changes in 
the disease such as alterations in wall thickness and plaque composition or volume. A 
third prevalent imaging technique is the intravascular ultrasound (IVUS) that 
compensates for the angiography by allowing the diagnostician to view the progression of 
the plaque and the effects of drug therapy on the disease, however, it is an invasive 
procedure. An upcoming technique is computed tomography (CT) which is a minimally 
invasive procedure that accesses the wall thickening of arteries. Similar to the CT, a high-
resolution magnetic resonance imaging (MRI) can also be used as a noninvasive modality 
Figure 2: Consequences of Plaque 
Rupture. Depicts the possible 
consequences of a growing, 
untreated plaque. It can either 
remain stable and result in 
occlusion or become unstable and 
rupture leading to myocardial 









Similar to MRI and CT, an additional noninvasive detection method is a positron 
emission tomography (PET) scan. One contrast agent used is 18F-fluorodeoxyglucose 
(FDG), a glucose analog, which is internalized at the site of plaque deposits. The 
accumulation of FDG can be detected via a PET scan, however, FDG can also be 
accumulated in any metabolically active cell making PET scans unreliable at times. 
Using FDGs also results in a high background due to myocardial uptake thus limiting its 
use for detection. Another contrast agent is 11C-PK 11195 which specifically binds to 
activated macrophages as seen at atherosclerosis plaque deposits. PET scans have also 
been used alongside CT scans to get more reliable results by detecting VCAM-1 or 
ICAM-1 expression via antibodies or peptides which have a high affinity for the area of 
interest in in vitro and ex vitro studies. These antibodies and peptides have been surface 
modified on SPIOs and microbubbles to attach to plaque deposits for further imaging via 
PET/CT scans similar to MR imaging.
1-3
 
JUSTIFICATION OF THE PROBLEM 
About 40% of the adult US population is at immediate risk of developing a 
cardiovascular disease, such as arthrosclerosis, with about 6-20% at risk of developing a 
coronary disorder within the next ten years. Most studies conducted within the field have 
focused on later stages of plaque detection. If imaged at a later stage, a plaque can rupture 
and lead to thrombosis, a heart attack, and even death. This study aims to conduct an in 
vitro study confirming the affinity of VCAM-1specific peptide surface modified 
superparamagnetic iron oxide nanoparticles (SPIOs) for early stages of atherosclerosis 
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plaque imaging. These results can later be translated into further analysis to use VCAM-1 

























VCAM-1 is present in active endothelial cells, macrophages, and smooth muscle 
cells (SMCs) and is upregulated in arthrosclerosis due to inflammation. It contributes to 
the recruitment and adhesion of lymphocytes to endothelial cells, forming plaque deposits 
1,6
. Currently, there are two developing techniques for detection, antibodies that bind to 
the surface of VCAM-1 expressing cells and specific peptides that are internalized by 
VCAM-1 expressing cells. Both methods have been studied extensively ex vivo as well as 
in vivo in order to determine which provides the most effective detection mechanism..  
VCAM-1 specific antibodies have been used in association with nanoparticles and 
microbubbles to detect arthrosclerosis for MR imaging in previously established ex vivo 
and in vivo studies 
8,9
. Ex vivo studies have shown that anti-VCAM-1 antibodies can be 
used to detect plaque, however, a low target-to-background ratio makes it difficult to 
differentiate lesions in in vivo mice models 
4,10
. This is confirmed by in vivo studies 




) mice with surface modified anti-VCAM1 
nanoparticles (VCAM-NPs) which were used to detect arthrosclerosis lesions via 
noninvasive MR imaging, however, at 1 hour most VCAM-NPs were still in circulation 
without clear signs of lesion receptor cell labeling. At 24 hours, accumulation of VCAM-
NPs was faintly detected within the lesions. These low intensity signals might have been 
due to the dissociation of the anti-VCAM1 antibodies from the target caused by the low 
bond formation rate of the antibodies. In rapid, high-shear circulation through vessels, 
contact time might not be adequate for antibody attachment to lesions 
4,11
. In order to 
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intensify these signals and improve the target-to-background ratio, a new approach was 
taken, cell internalization of VCAM-1 specific peptides. 
A key advantage of VCAM-1 specific peptides is their capability to amplify 
signals through cellular internalization which improves uptake >12-fold in comparison to 
anti-VCAM-1 antibodies (Figure 3) 
1,12
. Ex vivo studies have been conducted with 
VCAM-1 specific peptide sequence surface modified nanoparticles (VNPs) in order to 
determine the specificity of the particle for arthrosclerosis lesions in endothelial cells. An 
11-fold higher accumulation was seen in activated endothelial cells compared to other 
VCAM-1 expressing cells such as macrophages, thus suggesting that VNPs can be used 
to specifically target and detect arthrosclerosis 
1,6
. Similar to the VCAM-NPs mice 
model, an in vivo study was conducted on apoE
-/-
 mice via MRI to determine detection of 
lesions via peptide internalization. A change in signal intensity of MRI readings was 
detected with the accumulation of VNPs at arthrosclerosis regions which remained 
detectable for at least 24 hours 
1,6,7,13
. This confirms that VNPs provide a more intensified 
detection of activated endothelial cells in comparison with VCAM-NPs in an in vivo 
model.  
 
Figure 3: VCAM-1 specific peptide versus 
antibody affinity. Murine cardiac endothelial cells 
(MCECs) incubated with equimolar concentrations 
of anti-VCAM-FITC or VCAM-1 peptide 
(CVHSPNKKCGGSK(FITC)GK) for 2 hours at 
37˚C. Fluorescence detected via flow cytometry to 
compare uptake of peptide versus antibody for cells 
with overexpression of VCAM-1. A 12.1-fold higher 
fluorescence detected for the peptide (VP) than the 




VCAM-1 specific peptide sequences have also been used in ex vivo studies 
conducted on human carotid atheroma cells with a linear derivative of the cyclic peptide 
sequence used in Kelly et. al (VINP-28). This study suggests that VCAM-1 specific 
peptide sequences can be used in the future to detect arthrosclerosis in a clinical setting 
for humans 
1,6
. VINP-28 can also be used to tract the success of the arthrosclerosis 
treatment by detecting reductions in VCAM-1 expression as seen in apoE
-/-
 mice with an 
atherogenic diet that were statin-treated to reduce plaque buildup in vessel walls 
6
. This 
noninvasive, progression methodology can be applied to a human model to tract and 
analyze plaque development or depletion throughout the course of the disease. 
Both techniques for arthrosclerosis detection have proven effective in ex vivo 
models, however, the long term goal is to transfer this detection method from cell lines 
and animal models to a human compatible model. VCAM-1 specific cell internalizing 
peptides have proved to be the better prospective for transitioning due to its higher target-
to-background ratio in mice models as well as its ability to remain detectable for longer 
periods of time. The VCAM-1 specific peptide sequences have also been successfully 
tested in an ex vivo human cell model which broadens the possibility for this to be applied 
in vivo for humans as well as opens up its applicability to help detect other diseases with 
their respective specified peptide sequences. 
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CHAPTER 3 
MATERIALS & EXPERIMENTAL DESIGN 
Materials.  
Sodium hydroxide (NaOH), ammonium acetate (AA), hydroxylamine 
hydrochloride (HH), Tween 20, phosphate buffered saline (PBS), and bovine serum 
albumin (BSA) were purchased from Sigma. 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy (polyethylene glycol)-X] (DSPE-
PEG(2000)Methoxy) and 1,2-distearoyl-snglycero-3-phosphoethanolamine-N-
[maleimide(polyethylene glycol)-2000] (DSPE-PEG(2000)Maleimide) were purchased 
from Avanti. Hydrochloride (HCl) was purchased from VWR. VCAM-1 specific peptide 
(VINP) was purchased from Genescript. mVCAM/Fc Chimera antigen was purchased 
from R&D systems. All chemicals were used without further modification. 
Experimental Design 
Surface coating and functionalizing SPIOs.  
The SPIOs were functionalized with maleimide groups. The SPIOs were made 
water soluble via a dual solvent exchange method. Initially, DSPE-PEG(2000)Methoxy 
and DSPE-PEG(2000)Maleimide were dissolved in water to a final concentration of 10 
mg/mL. SPIOs and DSPE-PEG(2000) (90% Methoxy and 10% Maleimide) were mixed 
at a 1:4 weight ratio. Approximately, 100 µL of chloroform was added to the solution. 
Finally, DMSO was gradually added at 4 times the volume of the contents of the flask. 
The mixture was left to react for 1 hour before evaporating 20% of the DMSO via a 
vacuum pump. The entire reaction took place in a dry box. 
 10 
After the first solvent exchange, the SPIOs were made water soluble by gradually 
mixing the SPIO solution with water at a 1:5 volume ratio. The solution was filtered to 
remove the empty micelles via 3 rounds of centrifuge (100K Da cutoff size filters) at 
1,500 rcf for 15 minutes and 3 rounds of ultracentrifuge at 75,000 rcf for 30 minutes, 
both at 4˚C. The SPIOs were then filtered with a 25mm syringe-filter to remove any 
aggregates. 
Size determination by Dynamic Light Scattering (DLS).  
The diameter of the SPIOs was determined via dynamic light scattering 
(NICOMP Particle Sizing Systems, Santa Barbara, CA). The SPIO solution was diluted 
with Millipore water (mH2O) and size distribution data was collected for 30 minutes. 
Number-weighted NICOMP analysis was used to calculate the size distribution. 
Iron measurement by Ferrozine Assay.  
The iron content of the SPIOs was determined by mixing 50 µL of dilute SPIO 
solution with 50 µL of 12M HCl for 30 minutes at room temperature on a shaker. Next, 
the solution was mixed with 240 µL of 2M NaOH, 50 µL of 4N ammonium acetate, and 
110 µL of 5% hydroxylamine HCl for 30 minutes. After incubation, 50 µL of sample was 
mixed with 50 µL of 0.1% ferrozine solution and incubated for 15 minutes. Absorbance 
was read at 562 nm with 810 nm as reference. 
VCAM-1 specific peptide conjugation. 
After the SPIOs were filtered and quantified, VCAM-1 specific peptide was 
added at a 1:20 weight ratio (SPIO:peptide). The reaction was left at 4˚C overnight and 
then centrifuged 3 times at 1,500 rcf for 15 minutes at 4˚C. A DLS was conducted to 
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determine the change in particle size dispersion and a ferrozine assay was run to 
determine the new iron concentration. 
SPIO-peptide surface modification confirmation (ILISA).  
An ILISA was conducted to confirm VCAM-1 specific peptide surface 
modification of the SPIOs. ILSA plates were coated with 100 µL of 4 µg/mL 
mVCAM/Fc Chimera antigen overnight on a shaker at 4˚C. The plates were washed with 
wash buffer (0.05% Tween 20 in 1X Sigma PBS) three times. The plate was then blocked 
with 200 µL of 1X BSA in PBS and incubated overnight on a shaker at 4˚C. The next 
day, the wells were washed 3 times and 100 µL of SPIOs (0 – 100 µg/mL) were added to 
each well. The wells were incubated for 1 hour on a shaker at room temperature. The 
wells were washed again and 50 µL of 6M HCl was added to burn the adhered SPIOs. 
After 15 minutes, 70 µL of 4M NaOH and 80 µL of ILISA color (1.5mL 7.5N 
ammonium acetate, 2.5M of 5% hydroxylamine HCl, and 4mL of 0.1% ferrozine color) 
were added to each well and absorbance was read at 562 nm with 810 nm as reference. 
Confirming SPIO surface modification and in vitro affinity.  
The peptide-SPIOs were filtered via centrifuge, and DiI was added to a final 
concentration of 5ug/mL and incubated overnight at 4˚C. The SPIOs were filtered with 
centrifuge and a ferrozine was run again to check the concentration. The human umbilical 
vein endothelial cells (HUVECs) were split into 5 4-well chambers and incubated for a 
week until confluent. Lipopolysaccharide (LPS) was added to 9 wells at a final 
concentration of 100ng/mL and no LPS was added to another 9 wells. The cells were 
incubated with LPS for 6 hours at 37˚C. Next, the cells were washed and the DiI-peptide-
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SPIOs were added for 1 hour. The cells were washed and Hoechst and 4% 
paraformaldehyde were added to stain and fix the cells for DeltaVision imaging.  
Statistical Analysis.  
The images were analyzed with ImageJ. The data gathered from ImageJ was 




Confirming Surface Modification. 
 A DLS was conducted on the SPIOs before and after VCAM-1 peptide 
conjugation. Before surface modification, the radius of the 10% PEG-maleimide SPIO 
was 15.89 nm and after the addition of peptide, the radius increased to 20.63 nm. The 
increase in radius size confirms that there had been some modification to the surface of 
the SPIOs, however it did not specify what type of modification occurred. 
SPIO-peptide surface modification confirmation (ILISA).  
 In both trials, the ILISA plates were coated with 4µg/mL of VCAM-1 antigen and 
blocked with 1% BSA. Unmodified SPIOs was used as a control. In the first trial, 
concentrations of 0 - 100µg/mL SPIOs were incubated for 1 hour before reading. In 
general, there was a higher absorbance for the VCAM-1 modified SPIOs. There might 
have been some contamination for the 0 - 1.56µg/mL wells for the peptide-SPIO sample 






In the second trial, the same protocol was followed as before however, higher 
concentrations of SPIOs were used. Concentrations of 0 – 496µg/mL for VCAM-1 
peptide surface mondified SPIOs and concentrations of 0 - 733µg/mL for the control, 
unmodified SPIOs were used. Similar to trial 1, Figure 5 shows that the surface modifed 
SPIOs had a higher affinity for VCAM-1 antigen confirming the conjugation. 
Figure 4. Confirmation of VCAM-1 Peptide Surface Modification of 10% PEG-maleimide 
SPIOs via ILISA Trial 1. Plates were coated with 4ug/mL mVCAM antigen (n=1). 10% PEG-
maleimide SPIOs with no peptide was used as control. SPIOs were incubated for 1 hour at 
room temperature. Concentrations tested were 0 - 100µg/mL. There was a higher absorbance 






Confirming SPIO surface modification and in vitro affinity.  
Human umbilical vein endothelial cells (HUVECs) were induced with LPS 
(100ng/mL) to express VCAM-1 as would be seen in a patient with atherosclerosis. The 
cells were incuabated with surface modified VCAM-1 specific peptide SPIOs, scramble 
peptide SPIOs, and non-coated SPIOs for 1 hour and imaged via DeltaVision. Through 
this targeting study, it was determined that more VCAM-1 specific peptide SPIOs were 
present within cells induced with LPS thus confirming successful surface modification of 
the SPIOs as seen in Figure 6. 
Figure 5. Confirmation of VCAM-1 Peptide Surface Modification of 10% PEG-maleimide 
SPIOs via ILISA Trial 2. Plates were coated with 4ug/mL mVCAM antigen (n=1). 10% PEG-
maleimide SPIOs with no peptide was used as control. SPIOs were incubated for 1 hour at 
room temperature. Concentrations tested were 0 - 496µg/mL for peptide surface modified 
SPIOs and 0 - 733µg/mL for control SPIOs. There was a higher absorbance for the peptide 
coated SPIOs than for the non-surface modified SPIOs. 
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 In the first trial, the SPIOs were added at a concentration of 3ug/well for 1 hour. It 
was seen that most of the SPIOs were internalized by the cells. Non-modified SPIOs and 
scramble peptide SPIOs were used as controls. The peptide-SPIOs had the highest 
affinity for LPS induced cells. There was a 3-fold targeting increase from non-modified 
SPIOs and a 2-fold targeting increase from scramble-SPIOs as seen in Figure 7. It was 
also seen that there is non-specific binding for non-modified SPIOs and scramble-SPIOs 
with non-VCAM-1 expressing cells. 
 
Figure 6. Targeting Study. Confirmed that VCAM-1 specific peptide SPIOs (C) have a higher 
specificity and attraction for LPS induced cells than the control uncoated SPIOs (A) and scramble 






In the second set of trials, the same protocol was followed. Non-modified SPIOs 
and scramble peptide SPIOs were used as controls. There was a 7-fold and a 3.5 fold 
targeting increase from non-modified SPIOs and scramble-SPIOs to peptide-SPIOs, 
respectively. A 6-fold targeting increase was also seen between 0 and 100ng/mL LPS 
induced cells which were incubated with peptide-SPIOs as seen in Figure 8. 
Figure 7. Normalized Fluorescence Intensity of DiI coated SPIOs Trial 1. The bar graph 
shows the average ± standard error bars (n=1). The p-values after performing t-tests 
reaching statistical significance (p<.05) are marked on the graph: # indicates a significant 
difference between 0ng/mL and 100ng/mL LPS induced HUVECs targeting of uncoated 
SPIOs; * indicates a significant difference between the VINP coated SPIOs and the 

















Figure 8. Normalized Fluorescence Intensity of DiI coated SPIOs Trial 2. The bar graph 
shows the average ± standard error bars (n=3). The p-values after performing t-tests reaching 
statistical significance (p<.01) are marked on the graph: * indicates a significant difference 
between the peptide coated SPIOs and the uncoated and scramble coated SPIOs for 100ng/mL 
LPS induced HUVECs; # indicates a significant difference between 0 and 100ng/mL LPS 




The DLS, ILISA, and in vitro studies have shown that there is a higher attraction 
for peptide-SPIOs than non-modified SPIOs and scramble-SPIOs in LPS induced 
HUVECs representing in vivo atherosclerosis plaque cells. In the first trial, only a 3-fold 
targeting increase from non-modified SPIOs to peptide-SPIOs was seen while in the 
second trial there was a 7-fold increase. A similar inconsistency is seen between the 2-
fold targeting increase from scramble-SPIOs to peptide-SPIOs in the first trial compared 
to the 3.5-fold increase in the second trial. These inconsistencies might have been due to 
the sample size used in each trial. In the first trial, not enough product was retrieved to 
run more than one well per sample. The standard error was determined by averaging the 
data from three images per well. In the second trial, however three images were taken per 
well and three wells were used so that the results would be more reliable. 
 Another possibility for these inconsistencies is that when conducting the ferrozine 
of previous samples, a discrepancy was noticed between the concentration reading and 
the concentration of SPIOs added to the sample. The readings for the surface modified 
SPIOs was significantly lower than the readings for just the SPIOs which could mean that 
the peptide on the surface is distorting the iron content reading. A similar discrepancy 
was seen with DiI and non-DiI coated SPIOs. The DiI coated SPIOs had significantly 
lower concentrations of iron than the non-coated ones. Due to the discrepancies, the 
amount of iron added to each well might have been different which might also explain 
why the differences between the VCAM-1 coated and scramble coated SPIOs is smaller 
than expected from previous studies.
1,6
 In either case, there was a significance present 
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between the VCAM-1 coated SPIOs and the uncoated and scramble coated SPIOs which 
supports the hypothesis that VCAM-1 specific peptides modified SPIOs have a higher 
affinity for VCAM-1 expressing cells compared to the controls. 
 In trial 1, there was also a significant increase in the targeting between the 0 and 
100ng/mL LPS treated cells for non-coated SPIOs. Similar to the inconsistencies stated 
previously, this difference in targeting might have been due to the fact that only one well 
was imaged since in the second study, the 0 and 100 ng/mL had similar targeting. Similar 
to the non-coated SPIOs, a 6-fold increase was seen between the 0 and 100ng/mL 
peptide-SPIOs which was expected since the targeting should have increased when the 
cells were expressing VCAM-1. 
 Overall, these studies have shown that there is a significant increase in targeting 
of VCAM-1 expressing cells due to the surface modification of SPIOs with VCAM-1 
specific peptides. This study will need to be repeated to confirm these results with 
replicates before moving onto further testing and analysis. 
CONCLUSION 
These studies have shown a strong correlation between peptide-SPIOs and 
VCAM-1 expressing HUVECs as would be seen in plaque deposits during early 
development. Once these results are confirmed, this study can progress towards an ex 
vivo and in vivo models with atherosclerosis induced mice to test if the SPIOs will have a 






1. Kelly KA, Allport JR, Tsourkas A, Shinde-Patil VR, Josephson L, Weissleder R. 
Detection of vascular adhesion molecule-1 expression using a novel multimodal 
nanoparticle. Circ.Res. Feb 2005;96(3):327-336. 
2. Toth PP. Atherosclerosis: The Underlying Disease. The Journal of Family 
Practice. 2009;58(11). 
3. Boudi FB, Ahsan CH, III GS, TAlavera F, Compton SJ, Subhi Y. Coronary 
Artery Atherosclerosis. Medscape Reference-Drugs, Diseases & Procedures. 
2009. http://emedicine.medscape.com/article/153647-overview#showall. 
4. Kaufmann BA, Sanders JM, Davis C, et al. Molecular imaging of inflammation in 
atherosclerosis with targeted ultrasound detection of vascular cell adhesion 
molecule-1. Circulation. Jul 2007;116(3):276-284. 
5. Nahrendorf M, McCarthy JR, Libby P. Over a Hump for Imaging Atherosclerosis 
Nanobodies Visualize Vascular Cell Adhesion Molecule-1 in Inflamed Plaque. 
Circ.Res. Mar 2012;110(7):902-903. 
6. Nahrendorf M, Jaffer FA, Kelly KA, et al. Noninvasive vascular cell adhesion 
molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. 
Circulation. Oct 2006;114(14):1504-1511. 
7. Nahrendorf M, Keliher E, Panizzi P, et al. F-18-4V for PET-CT Imaging of 
VCAM-1 Expression in Atherosclerosis. JACC-Cardiovasc. Imag. Oct 
2009;2(10):1213-1222. 
8. Iiyama K, Hajra L, Iiyama M, et al. Patterns of vascular cell adhesion molecule-1 
and intercellular adhesion molecule-1 expression in rabbit and mouse 
 22 
atherosclerotic lesions and at sites predisposed to lesion formation. Circ.Res. Jul 
1999;85(2):199-207. 
9. Ferrante EA, Pickard JE, Rychak J, Klibanov A, Ley K. Dual targeting improves 
microbubble contrast agent adhesion to VCAM-1 and P-selectin under flow. 
Journal of Controlled Release. Dec 2009;140(2):100-107. 
10. Jaffer FA, Libby P, Weissleder R. Molecular and cellular imaging of 
atherosclerosis - Emerging applications. Journal of the American College of 
Cardiology. Apr 2006;47(7):1328-1338. 
11. Tsourkas A, Shinde-Patil VR, Kelly KA, et al. In vivo imaging of activated 
endothelium using an anti-VCAM-1 magnetooptical probe. Bioconjugate 
Chemistry. May-Jun 2005;16(3):576-581. 
12. Thorek DLJ, Chen AK, Czupryna J, Tsourkas A. Superparamagnetic Iron Oxide 
Nanoparticle Probes for Molecular Imaging. Annals of Biomedical Engineering. 
2006;34(1):23-38. 
13. Southworth R, Kaneda M, Chen JJ, et al. Renal vascular inflammation induced by 
Western diet in ApoE-null mice quantified by F-19 NMR of VCAM-1 targeted 
nanobeacons. Nanomedicine-Nanotechnology Biology and Medicine. Sep 
2009;5(3):359-367. 
